507462-51-3Relevant academic research and scientific papers
Tianqitinib, as well as preparation method and application thereof
-
Paragraph 0044; 0048-0050, (2019/07/10)
The invention provides tianqitinib, as well as a preparation method and application thereof, and provides an amide substituted azaindole compound or pharmaceutically acceptable salt thereof, or solvate or prodrug thereof. The compound has a structure as shown in a formula I. The compound can be used for remarkably inhibiting the enzyme activity of TRK at the molecular level, and has remarkable inhibiting effect on phosphorylation/activation of TRK at the cell level. Furthermore, the compound can be used for remarkably inhibiting growth of nude mice xenograft of human tumor cell lines, and hasa wide market application prospect.
Azaindole compound and preparation method and use thereof
-
Paragraph 0070-0071; 0076-0077, (2019/10/01)
The invention provides a compound shown in a formula I, or a pharmaceutically-acceptable salt, or prodrug or hydrate or solvate thereof. The invention further provides a preparation method and use ofthe compound. It is proved through experiments that the compound has a potential as a TPK inhibitor, has a significant inhibitory effect on tumor cells, particularly colon cancer cells, and has a verygood application prospect in the preparation of drugs for treating cancers.
PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH
-
Page/Page column 78; 79, (2018/08/12)
The invention relates to MKK4 (mitogen-activated protein kinase 4) and their use in promoting liver regeneration or reducing or preventing hepatocyte death. The MKK4 inhibitors selectively inhibit protein kinase MKK4 over protein kinases JNK and MKK7.
1H-PYRROLO[2,3-B] PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS
-
Paragraph 0102, (2015/02/18)
The inventions relates to compounds of (I) and therapeutic uses thereof: (I) The terms Z, Y, and R1 are as defined in the claims.
1H-PYRROLO[2,3-B] PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS
-
Page/Page column 23; 24, (2013/08/15)
The inventions relates to compounds of (I) and therapeutic uses thereof : (I) The terms Z, Y, and R1 are as defined in the claims.
